Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33914864.
- Also identified by DOI 10.1093/cid/ciab386.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2-882). Overall survival was 82% at day 42 and 70% at day 84.
Medical subject headings
- Aspergillosis
- Invasive Fungal Infections
- Mucormycosis
- Sinusitis